Efficacy and Safety of Ruxolitinib Cream Monotherapy in Patients Aged 2 Years and Older With Mild-to-Moderate Atopic Dermatitis: Results From 3 Large Randomized Phase 3 Studies
Simpson E, Eichenfield L, Papp K, Kircik L, Blauvelt A, Gold L, Zaenglein A, Lee L, Bunick C, Forman S, Holland K, Kallender H, Sturm D, Ren H, Armstrong A. Efficacy and Safety of Ruxolitinib Cream Monotherapy in Patients Aged 2 Years and Older With Mild-to-Moderate Atopic Dermatitis: Results From 3 Large Randomized Phase 3 Studies. Journal Of Allergy And Clinical Immunology 2025, 155: ab199. DOI: 10.1016/j.jaci.2024.12.618.Peer-Reviewed Original ResearchMild to moderate atopic dermatitisRandomized phase 3 studyPatients aged 2 yearsPhase 3 studyMild-to-moderateAge 2 yearsAtopic dermatitisMonotherapyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply